Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study (original) (raw)

Gallipoli, Paolo, Shepherd, Pat, Irvine, David, Drummond, Mark and Holyoake, Tessa(2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1111/j.1365-2141.2011.08653.x

Abstract

No abstract available.

Item Type: Articles (Letter)
Status: Published
Refereed: Yes
Glasgow Author(s) Enlighten ID: Drummond, Dr Mark and Irvine, Dr David and Holyoake, Professor Tessa and Gallipoli, Dr Paolo
Authors: Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M., and Holyoake, T.
College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name: British Journal of Haematology
Journal Abbr.: Brit. J. Haematol.
Publisher: Blackwell
ISSN: 0007-1048
ISSN (Online): 1365-2141
Published Online: 22 April 2011
Related URLs: PubMed

University Staff: Request a correction | Enlighten Editors: Update this record